Abstract Matrix metalloproteinases (MMPs) have been implicated in human immunodeficiency virus (HIV)-associated neurological injury; however, this relationship has not been studied early in infection. Plasma levels of MMP-1, MMP-2, MMP-7, MMP-9, and MMP-10 measured using Luminex technology (Austin, TX, USA) were compared in 52 HIV and 21 seronegative participants of the Chicago Early HIV Infection study. MMP levels were also examined in HIV subgroups defined by antibody reactivity, viremia, and antiretroviral status, as well as in available cerebrospinal fluid (CSF) samples (n =9). MMPs were evaluated for patterns of relationship to cognitive function and to quantitative magnetic resonance measurements of the brain derived in vivo. Plasma MMP-2 levels were significantly reduced in early HIV infection and correlated with altered white matter integrity and atrophic brain changes. MMP-9 levels were higher in the treated subgroup than in the naïve HIV subgroup. Only MMP-2 and MMP-9 were detected in the CSF; CSF MMP-2 correlated with white matter integrity and with volumetric changes in basal ganglia. Relationships with cognitive function were also identified. MMP-2 levels in plasma and in CSF correspond to early changes in brain structure and function. These findings establish a link between MMPs and neurological status previously unidentified in early HIV infection.
Introduction
Human immunodeficiency virus (HIV) infection results in serious central nervous system injury and cognitive deterioration in many patients. Neurological injury has been ascribed to the deleterious effects of unrelenting immune activation (McArthur et al. 2005) . Matrix metalloproteinases (MMPs) have been investigated in this setting (Conant et al. 1999; Liuzzi et al. 2000; Louboutin et al. 2010; Ragin et al. 2009; Van Lint and Libert 2007) because of their involvement in the regulation of neuroinflammation (McQuibban et al. 2002) , blood-brain barrier permeability (Louboutin et al. 2010) , and cell migration (Agrawal et al. 2008; Sternlicht and Werb 2001) . MMPs are extracellular proteases that may facilitate infiltration of the central nervous system by infected monocytes by influencing blood-brain barrier permeability (Louboutin et al. 2010; Van Lint and Libert 2007) . MMP activity is elevated in the cerebrospinal fluid (CSF) of infected patients (Conant et al. 1999; Liuzzi et al. 2000) , and plasma MMP levels correlate with the severity of brain atrophy quantified in vivo in advanced infection (Ragin et al. 2009 . MMPs may be of particular relevance in early infection. Viral invasion of the brain occurs soon after initial infection (Chiodi et al. 1988; Davis et al. 1992) , causing neuroinflammation and potentially establishing a viral reservoir. MMP levels and relationships to brain changes in this period, however, are largely unknown.
This study determined plasma levels of MMP-1 (collagenase-1), MMP-2 (gelatinase A), MMP-7 (matrilysin), MMP-9 (gelatinase B), and MMP-10 (stromelysin-2) in participants of the Chicago Early HIV Infection study, a cohort (n =52) infected, on average, <1 year. This analysis is also distinguished by inclusion of an age-matched seronegative control group (n =21); information concerning normative plasma MMP levels is very limited. MMPs were also determined in HIV subgroups based on antibody reactivity (nonreactive and reactive), antiretroviral treatment status (ARVand naïve), and viremia (controlled and uncontrolled, i.e., viral load >50 copies/mL). MMP levels in CSF, available for nine of the infected subjects, were also examined. To evaluate MMP relationships with neurological status, brain volumetric measurements were derived using high-resolution neuroanatomic imaging. Diffusion tensor imaging (DTI) was used to assess microstructural alterations (Le Bihan 2003) . DTI parameters include fractional anisotropy (FA), which is higher in intact axons and systematically reduced with loss of white matter integrity, and mean diffusivity (MD), which is sensitive to microstructural changes that increase (e.g., atrophy) or decrease (e.g., edema) overall molecular diffusion. MMPs were also evaluated for relationships to clinical status measures and cognitive function measured by a comprehensive neuropsychological evaluation.
Methods

Participants
For enrollment in the Chicago Early HIV Infection cohort study, individuals with self-reported HIV infection were evaluated for the likelihood of recent infection based on either a prior negative test result or compelling available information concerning probable time of initial viral exposure. Exclusion criteria for study entry included history of chronic neurological disorder, head injury, radiation or chemotherapy in the prior 30 days, uncontrolled seizure disorders, experimental drugs or any vaccination within the past 15 days, inability to understand due to mental condition, chronic or active alcohol abuse, chronic or active drug abuse, pregnancy, opportunistic infection, cancer, other medical condition (heart, liver, or kidney), and magnetic resonance (MR) contraindication (metal implants or claustrophobia). The Institutional Review Board of Northwestern University approved this investigation, and all subjects signed an informed consent document.
Clinical status
Blood samples were collected from all subjects. Serostatus was determined by ELISA and Western blot. Clinical measures for HIV subjects included CD4 + cell count, CD8 + cell count, CD4/ CD8 ratio, hemoglobin, and plasma HIV RNA copies per milliliter (viral load). CSF samples were collected from nine HIV subjects consenting to lumbar puncture. To assess relative recency of infection, samples from the HIV subjects were also analyzed using an early infection assay (Blood Systems Research Institute, San Francisco, CA, USA) designed to evaluate individuals whose antibody response against the virus is still evolving (Keating et al. 2012) . For the HIV group (n =52), the mean estimated period from initial infection was <1 year. Thirteen of these subjects were antibody nonreactive and conservatively estimated to be infected <70 days. In the HIV group, absolute CD4 + cell counts ranged from 139 to 1,282/mm 3 , with a mean of 548±252/mm 3 and a median of 509/mm 3 . Log (base 10) plasma viral load (copies per milliliter) ranged from undetectable to 5.54, with a mean of 3.18±1.34. Twenty-seven HIV subjects were treatment naïve. Of those receiving treatment, the majority were on efavirenz/tenofovir/emtricitabine (trade name Atripla).
MMP Luminex assays
MMP profiles were measured in plasma for all subjects and in CSF for consenting HIV subjects. Samples were assayed using the MILLIPLEX MAP Human MMP Panel 2 (Millipore, Billerica, MA, USA) including MMP-1, MMP-2, MMP-7, MMP-9, and MMP-10 using a 1:20 dilution and following the manufacturer's protocols. MMP-1, MMP-2, MMP-7, and MMP-10 antibodies bind to both proMMP and active forms of the molecules. Because the antibodies used are proprietary, the exact binding specificity for MMP-9 is unavailable. The lower limits of detection for MMPs were 54, 468.4, 965, 24.7, and 49 .1 pg/mL, respectively. Standard curves were run in duplicate wells on each plate using reagents provided by the manufacturer. Samples were run in duplicate, acquired, and analyzed on a LABScan 100 analyzer (Luminex) using Bio-Plex Manager 6.0 Software (Bio-Rad, Hercules, CA, USA). Each run included internal and external controls, all quality control reagents were within range, and coefficient of variation was an average of 14 % for all controls.
MRI analysis
Radiological variables included volumetric and DTI measurements derived in vivo for major brain tissue classes and specific neuroanatomic structures. Brain regions were segmented based on high-resolution 3D MPRAGE images and automated algorithms including SIENAX and Freesurfer. A novel automated "autoregional" 3D volume of interest image analysis strategy ) was used to derive DTI parameters, including FA and MD. Details are presented in the Supplementary methods.
Neuropsychological assessments
All participants were evaluated with a neuropsychological test battery that assessed motor skills, cognitive flexibility, abstraction, verbal memory, visual memory, and visuoconstructional skills. Details and references are in the Supplementary methods.
Statistical methods
Primary variables for analysis included plasma MMP-1, MMP-2, MMP-7, MMP-9, and MMP-10 levels for all subjects. CSF MMP-2 and MMP-9 levels were available for nine consenting HIV subjects (levels of CSF MMP-1, MMP-7, and MMP-10 were undetectable for all nine samples). Distributional assumptions were evaluated prior to analysis. MMP group comparisons were accomplished using t tests or Mann-Whitney tests. For comparisons involving three subgroups, analysis of variance (ANOVA) or Kruskal-Wallis tests were used. Pearson or Spearman correlation coefficients were used to determine the relationships between MMPs and the imaging, clinical, and neuropsychological variables. Missing variables were excluded pairwise for all analyses. A significance level of 0.05 was used for a priori analyses. The Bonferroni correction (0.05/n) was used to correct for multiplicity. Analyses were executed using IBM SPSS 20.0.0 (Chicago, IL, USA).
Results
This study included 52 HIV seropositive (46 males, 6 females; mean age, 33.2±9.9) and 21 seronegative (16 males, 5 females; mean age, 31.4±8.8) participants (Table 1) . HIV and control groups did not differ in age (p =0.471), gender (p =0.188), race (p =0.317), or education (p =0.282). North American Adult Reading Test score, a measure of general intellectual performance (Blair and Spreen 1989) , also did not differ (p =0.072). Clinical characteristics of the HIV group are presented in Table 2 .
Plasma MMP-2 levels were reduced in the HIV group compared to the control group (p <0.001) ( Table 3) . In further analysis, MMP-2 also differed in HIV antibody-reactive/ nonreactive subgroups and controls (p <0.001; Table 3 ). The reduction in MMP-2 levels was more pronounced in HIV subjects who had developed an antibody response than in the most recently infected (antibody nonreactive) subjects (Fig. 1) .
Comparison of MMP levels in ARV-naïve, ARV-initiated, and control groups indicated significant differences for MMP-2 (p <0.001) and for MMP-9 (p =0.050) ( Table 3) . MMP-9 levels were significantly higher in the ARV-initiated than ARV-naïve subgroup (p =0.016). MMP-2 showed reductions in both ARV-naïve and ARV-initiated groups compared to controls (p =0.002; p <0.001). Further analysis (Table S1) indicated that MMP-2 levels did not differ between viremic and aviremic HIV subgroups and were reduced in both HIV subgroups (p <0.001; p <0.001) compared to controls. Table 4 presents MMP correlations with Freesurfer volumetric measurements of localized brain regions and landmarks, including results significant at both uncorrected (p <0.05) and Bonferroni-corrected (p <0.003) levels. Plasma MMP-1 was significantly correlated with volumetric measurements of cerebral white matter (p =0.036), brain stem (p =0.016), and fourth ventricle (p =0.005). MMP-7 was correlated with the amygdala (p =0.034) and cerebellum cortex (p =0.045). MMP-9 was correlated with the splenium (p =0.013) and fourth ventricle (p = 0.035). MMP-10 was correlated with the cerebral white matter (p =0.031) and fourth ventricle (p =0.037). CSF MMP-2 was correlated with the caudate (p =0.036), putamen (p =0.030), accumbens (p =0.020), and pallidum (p =0.002) volumes. CSF MMP-9 was correlated with the inferior lateral ventricle (p =0.050). No significant correlations were identified with SIENAX measurements of the major brain constituent tissue classes (i.e., total gray matter, white matter, or CSF) (Table S2) . MMPs were also correlated with autoregionally determined DTI parameters (Hutten et al. 2011; Wu et al. 2012) . The studied microstructural measures included FA, which reflects loss of white matter integrity, and MD, which is sensitive to microstructural changes that increase (e.g., atrophy) or decrease (e.g., edema) diffusion (Table 5) . Regions in italics indicate significant correlations at the Bonferroni-corrected level of 0.05/9. For FA, MMP-1 was correlated with corpus callosum (p =0.037), cerebral white matter (p =0.010), and hippocampus (p =0.048) anisotropy. MMP-2 was correlated with cerebral white matter (p =0.013) and whole brain white matter (p =0.003) anisotropy. CSF MMP-2 was correlated with cerebral white matter (p =0.031) and corpus callosum (p =0.023) anisotropy. For MD, MMP-2 was correlated with whole brain (p =0.001), cerebral cortex (p = 0.001), cerebral white matter (p =0.002), putamen (p =0.013), thalamus (p =0.023), and whole brain white matter (p =0.004) diffusivity. MMP-7 was correlated with whole brain (p =0.010), caudate (p =0.012), and putamen (p =0.020) diffusivity. MMP-10 was correlated with hippocampus diffusivity (p =0.031). CSF MMP-9 was correlated with caudate diffusivity (p =0.024). Table 6 presents correlations with clinical measures in HIV subjects. MMP-2 was correlated with the CD4/CD8 ratio (p =0.049). MMP-7 was correlated with viral load (p =0.044). CSF MMP-2 was correlated with CD8 + cell count (p =0.007). Neuropsychological correlations are presented in Table 7 . MMP-1 was correlated with Rey auditory verbal memory (p =0.019), letter-number sequencing (p =0.019), and trail-making performance (p =0.003). MMP-7 was correlated with timed gait (p = 0.003). MMP-10 was correlated with trail-making (p =0.035). CSF MMP-2 was correlated with grooved pegboard performance (p =0.049). CSF MMP-9 was correlated with verbal fluency (p =0.042). Neuropsychological correlations failed to meet the more conservative Bonferroni criteria.
Discussion
This study analyzed MMP-1, MMP-2, MMP-7, MMP-9, and MMP-10 levels in an early HIV infection cohort and in an agematched control group. Of these, MMP-2 showed the most prominent relationship with brain status in early HIV infection. Circulating MMP-2 levels were reduced in the early HIV group compared to controls (Table 3 ) and were correlated with DTI measures (FA and MD), reflecting microstructural brain alterations (Table 5 ). Specific correlates of plasma MMP-2 included loss of white matter integrity (reduced anisotropy), as well as atrophic alterations (increased diffusivity) in whole brain, brain white matter, cerebral cortex, and cerebral white matter. MMP-2 relationships with loss of cerebral white matter integrity and with increased diffusivity in the putamen and thalamus were also observed. Notably, correlates of MMP-2 mirror brain regions vulnerable to injury in HIV infection. Autopsy and in vivo imaging studies in HIV infection have shown similar abnormalities in white matter and basal ganglia, as well as abject brain atrophy (Chen et al. 2009; Filippi et al. 2001; Hutten et al. 2011; Navia et al. 1986; Thompson et al. 2005; Wohlschlaeger et al. 2009 ). Analysis of HIV subgroups suggests that plasma MMP-2 levels decline over the course of HIV. Plasma MMP-2 reduction was more marked in the antibody-reactive than in the early nonreactive HIV subgroup compared to controls (Fig. 1) . In addition, plasma MMP-2 levels correlated with CD4/CD8 ratio (Table 6 ), a prognostic marker of systemic HIV progression (Taylor et al. 1989) . The relative plasma MMP-2 reduction was not mitigated by ARVs; levels were more markedly reduced in ARV-treated subgroup than ARV-naïve subgroup, despite a similar duration of infection (Table 3 ). ARV response for certain patients may have been limited because of the early infection period and short duration of treatment. To account for this, viremia status (controlled vs. uncontrolled) was analyzed, supporting the results for the treatment comparison (Table S1) . MMP-9 levels in plasma were higher in the ARV-initiated than naïve HIV subgroup, possibly reflecting the effects of ARV activity.
MMP-2 and MMP-9 were the only MMPs detected in the CSF and were detected in all available samples (n =9). Because CSF was not acquired from healthy controls, direct group comparisons were precluded. CSF MMP-9 levels in the Chicago Early HIV cohort were generally higher than levels reported for controls in other studies; results reported for CSF MMP-2 levels in controls, however, were widely variable across different studies (Bjerke et al. 2011; Leppert et al. 1998; Niebroj-Dobosz et al. 2010; Yushchenko et al. 2000) . Nevertheless, the findings suggest elevated CSF MMP-2 levels in early HIV infection. Evidence from in vivo (Conant et al. 1999; Sporer et al. 1998 ), autopsy (Johnston et al. 2000) , and animal (Johnston et al. 2000 ) studies indicate elevated brain MMP levels in HIV infection. In this investigation, CSF MMP-2 levels were correlated with loss of white matter integrity (anisotropy) in the cerebral white matter and corpus callosum, the largest white matter fiber tract in the brain. CSF MMP-2 levels were also correlated with numerous localized volumetric measurements of basal ganglia, including the caudate, putamen, pallidum, and accumbens (Table 4) . This region is vulnerable to injury in more advanced HIV infection (Becker et al. 2011; Berger and Arendt 2000) .
MMP-2 and MMP-9 are gelatinases that influence bloodbrain barrier permeability (Louboutin et al. 2010 ). In the brain, elevated MMP-2 levels secreted by infected macrophages, microglia, and astrocytes may have neurotoxic effects (Zhang et al. 2003) . Elevated MMP-2 and MMP-9 levels have been quantified in brain tissue samples from the cerebral cortex and basal ganglia of HIV encephalitis patients and correlate with CD14 mRNA levels (Ghorpade et al. 2001) . Correlations with CD14 suggest that elevated MMP levels may be due to increased numbers of immune-activated microglia and perivascular macrophages and to monocyte transmigration.
Interest in circulating factors (i.e., in plasma) follows from evidence implicating systemic monocyte activation in brain injury and cognitive deterioration in HIV infection (Gartner 2000) . The trafficking of blood-borne, activated (CD14 + ) monocytes to the brain is the presumed vehicle for viral entry. Results from this investigation indicate reduced MMP-2 levels in plasma and likely elevated levels in the brain in HIV infection compared to controls. Other evidence suggests MMP-2 involvement in neurodegeneration. Similar findings of decreased MMP-2 levels in plasma and increased MMP-2 activity in the brain have been reported in Alzheimer's disease, where MMP-2 may play a role in the clearance of amyloid-β plaques (Lim et al. 2011) .
MMP-2 levels were nearly an order of magnitude higher in the plasma than in the CSF (n =9; plasma, 36,462±11,461 pg/ mL vs. CSF, 6,700±2,297 pg/mL). Sources of circulating MMP-2 include T lymphocytes and activated macrophages (Oviedo-Orta et al. 2008) . In lymphoid tissue, the ratio of MMP-2 to its inhibitor TIMP-2 is decreased in HIV compared to control subjects (Diaz et al. 2010) . Decreased MMP-2 in plasma and in lymphoid tissue may reflect the massive T cell destruction that occurs early in HIV infection in association with unchecked viral expansion. The Millipore antibody used in this study detects both proMMP and active forms of MMP-2; therefore, the observed reduction is unlikely to be accounted for by the possibility that MMPs are being cleaved and activated (with the detected domain being degraded). Elevated MMP-2 in the CSF may reflect changes occurring in association with increased permeability of the blood-brain barrier in early infection together with constitutively higher levels of MMP-2 in plasma (Louboutin and Strayer 2012; Xu et al. 2012) .
It is important to appreciate that MMPs levels in plasma and CSF, as well as of individual MMPs, are not independent. MMPs participate in a complex protease web, and their effects are determined by factors such as substrate specificity, distribution, and regulatory proteins (Sternlicht and Werb 2001) . MMP-2 and MMP-9 are gelatinases which cleave specific collagen types more effectively than other MMPs. MMP-1 is an interstitial collagenase with preferential affinity toward other collagen types, MMP-7 is a more potent protoglycanase and elastase, and MMP-10 is a stromelysin with specificity for laminin, fibronectin, and proteoglycans (Webster and Crowe 2006) . Dysregulated or prolonged MMP activity may pose considerable risk of tissue destruction. Collagen type IV, a substrate of MMP-2 and MMP-9 in the extracellular matrix, is reduced in the brain in HIV-infected patients (Buttner et al. 1996) . MMPs may also alter the biologic activity of cytokines and chemokines (Van Lint and Libert 2007) and modulate the neurotoxicity of HIV viral proteins (Rumbaugh et al. 2006) . It is also important to appreciate that MMPs may also play beneficial roles. MMP-1, for example, is elevated in injured tissues, including the brain (Leake et al. 2000) where it may attenuate HIV neurotoxicity in white matter (Parks et al. 2004; Rumbaugh et al. 2006) . In this investigation, plasma MMP-1 levels correlated with anisotropy in cerebral white matter, possibly reflecting this process (Table 5) . MMP-7 also correlated with diffusivity throughout the brain and was inversely correlated with viral load, consistent with findings in advanced HIV (Ragin et al. 2009 . MMPs are involved in regulating neuroinflammation and may figure prominently in aberrant immune activation underlying injury to the brain in HIV infection. In chronic inflammation, all MMPs may be present (Ra and Parks 2007) . In vitro findings indicate MMP changes in response to ARVs (Gramegna et al. 2011; Latronico et al. 2007) , suggesting that MMPs may represent potential therapeutic targets. However, evidence of MMP physiologic significance in cognitive function underscores the necessity of further studies before MMPs are targeted for clinical intervention. This investigation evaluated five different MMPs in plasma and in CSF for patterns of relationship with MR-quantified brain status in an early infection cohort. In particular, MMP-2 displayed patterns of relationship with measurements of multiple brain regions, distinguished stages of the immune response to HIV, and correlated with clinical markers of HIV disease progression. Imaging correlates of plasma MMP-2 levels correspond to regions vulnerable to brain injury in the initial stages ) and later stages of HIV infection. Further prospective studies are necessary to determine the prognostic significance of MMPs. Taken together, these findings support a role of MMP-2 in HIV-associated neurological injury in the earliest stages of infection and suggest potential utility as an early plasma marker of neurological vulnerability.
